Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9109123 | 0.85 | BCL2 (0.49) | CES1ALDH1A1GAAPOLBKDM4E | |
| SCHEMBL20835844 | 0.82 | ALDH1A1 (0.68) | ALDH1A1GAAPOLBKDM4ETP53 | |
| SCHEMBL512864 | 0.82 | ALDH1A1 (0.68) | ALDH1A1GAAPOLBKDM4ETP53 | |
| SCHEMBL10201311 | 0.82 | ALDH1A1 (0.68) | ALDH1A1GAAPOLBKDM4ETP53 | |
| SCHEMBL32691229 | 0.82 | ALDH1A1 (0.68) | ALDH1A1GAAPOLBKDM4ETP53 | |
| SCHEMBL281661 | 0.81 | ALDH3A1 (0.48) | ALDH1A1KDM4EAGTR1ALDH2ALDH3A1 | |
| SCHEMBL1895648 | 0.81 | CUL4A (0.53) | CES1ALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL18258640 | 0.80 | KMT2A (0.61) | CES1ALDH1A1GAAKDM4ETTR | |
| SCHEMBL18974288 | 0.80 | KMT2A (0.61) | CES1ALDH1A1GAAKDM4ETTR | |
| SCHEMBL281623 | 0.80 | KMT2A (0.61) | CES1ALDH1A1GAAKDM4ETTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2428515-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| EP-2073806-B1 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-15 | — | — | EP | disclosed |
| EP-1888595-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-8106087-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20110251224-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-7935721-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2011-05-03 | — | — | US | disclosed |
| US-7700641-B2 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| EP-2032584-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | Wyeth (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | WYETH (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2007146138-A2 | THIADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WYETH (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172282-A9 | USE OF SPIRO-OXINDOLE COMPOUNDS AS THERAPEUTIC AGENTS | KLK3, REN, AVPR1B | CES1 1859/4885ALDH1A1 1202/4885GAA 4380/4885 |
| US-20060252812-A1 | Spiro-oxindole compounds and their uses as therapeutic agents | OPRK1, OPRD1, SCN3A | CES1 3669/4885ALDH1A1 838/4885GAA 4464/4885 |
| US-20110251224-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | OPRK1, OPRD1, SCN3A | CES1 3669/4885ALDH1A1 838/4885GAA 4464/4885 |
| US-20080125469-A1 | Thiadiazole compounds and methods of use thereof | ADAMTS5, ADAMTS1, TIMP3 | CES1 1357/4885ALDH1A1 388/4885GAA 2287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.